Research

Hormonal

Pharmacological re-activation of AMPK in the liver suppresses hepatic steatosis by inhibiting lipid synthesis and stimulating fatty acid oxidation, whereas genetic loss of AMPK does not cause fatty liver development.

While low AMPK activity is linked to fatty liver, simply having low activity doesn't cause the fat accumulation. However, drugs that activate AMPK (like metformin or specific activators) can help reduce liver fat by blocking fat creation and increasing fat burning. This suggests that targeting AMPK is a valid treatment strategy for fatty liver, even if low AMPK itself isn't the initial cause.

GoodQualifiesHIGH confidence
Unexpectedly, we show here that liver-specific AMPK KO mice display normal hepatic lipid homeostasis and are not prone to fatty liver development... In contrast, we found that pharmacological re-activation of downregulated AMPK in fatty liver is sufficient to normalize hepatic lipid content.
Nadia Boudaba et al. · EBioMedicine · 2018

Why this rating

High-quality genetic mouse models (liver-specific KO) combined with in vitro human hepatocyte data and pharmacological validation.

Source

AMPK Re-Activation Suppresses Hepatic Steatosis but its Downregulation Does Not Promote Fatty Liver Development

Nadia Boudaba et al. · EBioMedicine · 2018

DOI 10.1016/j.ebiom.2018.01.008

mechanism_onlyCited 210×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →